BUZZ-Dermata <a href="https://laohu8.com/S/LENZ">Therapeutics</a> climbs on acne product shift** Shares of drug developer Dermata Therapeutics DRMA.O rise 9.8% to $5.70 premarket
** Co says it is shifting focus to over-the-counter dermatology products that can be sold directly to consumers
** Co plans to develop a once-weekly acne kit using an approved OTC active ingredient combined with its Spongilla technology
** The acne kit is expected to launch in mid-2026, co says
** As part of its shift, co withdrew its marketing application for Xyngari from the FDA, a drug it was developing to treat moderate-to-severe rosacea
** As of last close, stock down 61.6% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.